Inaugural Leaders in Precision Medicine

Many believe that personalized medicine technologies, such as next-generation sequencing, have propelled us to the tipping point of a new era in healthcare - precision medicine. Stakeholders are now faced with the perplexing economic and regulatory issues of balancing the promise of new genome-driven medicines with the associated trade-offs of longer and higher development risk for Rx and CDx innovators, increased evidence standards for regulators, reimbursement concerns for patients, and unclear value for payers. This symposium will feature discussions from drug/diagnostic innovators, regulators, providers and payers to discuss major challenges and potential pathways for delivering precision medicines.